Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

Stock Information for Medexus Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Medexus Pharmaceuticals Inc.

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Canadian Investment Regulatory Organization Trade Resumption - MDP
Canadian Investment Regulatory Organization Trading Halt - MDP
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.